Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298905 | 1.00 | CPA1 (0.46) | CPA1ALDH1A1CYP2C19MMP8LMNA | |
| SCHEMBL578526 | 0.94 | ALDH1A1 (0.50) | CPA1ALDH1A1CYP2C19MMP8LMNA | |
| SCHEMBL2541159 | 0.94 | ALDH1A1 (0.50) | CPA1ALDH1A1CYP2C19MMP8LMNA | |
| SCHEMBL2541157 | 0.94 | ALDH1A1 (0.50) | CPA1ALDH1A1CYP2C19MMP8LMNA | |
| SCHEMBL16659739 | 0.90 | ALDH1A1 (0.44) | CPA1ALDH1A1CYP2C19MMP8LMNA | |
| SCHEMBL2418725 | 0.90 | ALDH1A1 (0.44) | CPA1ALDH1A1CYP2C19MMP8LMNA | |
| SCHEMBL16659740 | 0.90 | ALDH1A1 (0.44) | CPA1ALDH1A1CYP2C19MMP8LMNA | |
| SCHEMBL5243446 | 0.87 | ALDH1A1 (0.59) | CPA1ALDH1A1CYP2C19LMNAKMT2A | |
| SCHEMBL18106499 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CYP2C19LMNANPC1KMT2A | |
| SCHEMBL18579453 | 0.86 | ALDH1A1 (0.44) | CPA1ALDH1A1CYP2C19LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640361-B9 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2298730-B1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-9073823-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-1640361-B1 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-05-27 | — | — | EP | disclosed |
| CN-102459194-B | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2014-10-29 | — | — | CN | disclosed |
| US-8791295-B2 | Method of producing purified optically acitve 4-amino-3-(substituted phenyl)butanoic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| CN-102056891-B | Method of producing purified optically active 4-amino-3-(substituted phenyl)butanoic acid compound | SUMITOMO CHEMICAL CO | 2014-06-25 | — | — | CN | disclosed |
| US-8580804-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2418204-B1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | UNIV KYOTO (JP) | 2013-07-24 | — | — | EP | disclosed |
| CN-102459194-A | Compound having heterocyclic skeleton and method for producing optically active compound using the same as asymmetric catalyst | UNIV KYOTO | 2012-05-16 | — | — | CN | disclosed |
| CN-102056891-A | Method of producing purified optically active 4-amino-3-(substituted phenyl)butanoic acid compound | SUMITOMO CHEMICAL CO | 2011-05-11 | — | — | CN | disclosed |
| CN-1839116-B | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL CO | 2010-05-26 | — | — | CN | disclosed |
| US-7632970-B2 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| CN-100354249-C | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGAKU (JP) | 2007-12-12 | — | — | CN | disclosed |
| CN-1839116-A | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL CO (JP) | 2006-09-27 | — | — | CN | disclosed |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1640361-A2 | ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
| CN-1626501-A | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGAKU (JP) | 2005-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | COASY, LSS, INF2 | CPA1 4580/4885ALDH1A1 2537/4885CYP2C19 574/4885 |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | RAD18, UTP18, UBE2G2 | CPA1 3471/4885ALDH1A1 2730/4885CYP2C19 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.